Chemotherapy Induced Anemia Market Expected to Reach $5 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Chemotherapy Induced Anemia Market," The chemotherapy induced anemia market size was valued at $2.7 billion in 2022, and is estimated to reach $5.0 billion by 2032, growing at a CAGR of 6.3% from 2023 to 2032. Chemotherapy-induced anemia (CIA) is a common side effect of chemotherapy. CIA occurs when chemotherapy drugs damage or destroy red blood cells, which are responsible for carrying oxygen throughout the body. As a result, patients with CIA may experience symptoms such as fatigue, shortness of breath, dizziness, and weakness. CIA can be managed through a variety of treatments, including erythropoiesis-stimulating agents (ESAs), which are medications that stimulate the production of red blood cells. ESAs can help to improve symptoms of anemia in cancer patients undergoing chemotherapy. Other treatments for CIA are blood transfusions and iron supplements.

Chemotherapy induced anemia market trends include increase in incidences of anemia among cancer patients, rise in awareness about chemotherapy induced anemia, presence of chemotherapy induced anemia industry and surge in ageing population. As the incidence of cancer continues to rise, the demand for effective treatments for chemotherapy-induced anemia is also increasing. For instance, in April 2022, the National Institute of Health (NIH) estimated that about 22.7% to 63% of cancer patients have anemia.

However, the high cost of erythropoiesis-stimulating agents used to treat chemotherapy induced anemia, and blood transfusion restrains the market growth. Furthermore, potential risks associated with the use of erythropoiesis-stimulating agents such as hypertension, venous thromboembolism, blood clots, and myocardial infraction, limit the use of these drugs which negatively impact the market growth.

The chemotherapy induced anemia market share is segmented on the basis of grade, treatment, end user, and region. On the basis of grade, the market is classified into grade 1, grade 2, and grade 3 & 4. As per treatment, the market is segmented into blood transfusion, erythropoietin-stimulating agents, and iron & other supplements. On the basis of end user, the market is divided into hospitals, cancer centers, and others (cancer research center, cancer rehabilitation center, and home use).

Region wise, the chemotherapy induced anemia market analysis across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

On the basis of grade, the grade 1 segment dominated the market in 2022, and is the fastest growing segment during the forecast period. This is attributed to early diagnosis of grade 1 chemotherapy induced anemia in cancer patients and rise in awareness about early management of chemotherapy induced anemia. On the basis of treatment, the erythropoietin-stimulating agents segment dominated the market in 2022 and is the fastest growing segment during the forecast period. As it is highly effective at increasing red blood cell production and improving hemoglobin levels in patients with anemia and it is convenient to use by home bound patients.

As per end user, the hospital segment dominated the global market in 2022 and is expected to be the fastest growing segment during the forecast period. This is attributed to the rise in incidences of cancer and many hospitals offer insurance coverage for cancer patients.

Region wise, North America had the highest chemotherapy induced anemia market share in 2022, and is expected to maintain its lead during the forecast period, owing to high prevalence of cancer, easy accessibility of treatments, development of novel therapies for treating chemotherapy induced anemia, presence of chemotherapy induced anemia industry and increase in geriatric population who are more susceptible to develop cancer and anemia in this region. However, Asia-Pacific is expected to exhibit fastest growth during the chemotherapy induced anemia market forecast period, owing to rise in incidence of cancer due to changing lifestyles and aging population has led to a greater demand for chemotherapy treatments, surge in healthcare expenditure, and increase in awareness of cancer and its treatment options.

The COVID-19 pandemic has created several challenges for the chemotherapy induced anemia market size, such as disruption in the supply chains of many pharmaceutical companies, leading to shortages of therapeutic drugs and delaying the R&D activities new products. In addition, the pandemic has forced many healthcare facilities to prioritize COVID-19 patients, this has led to delays in the diagnosis and treatment of other medical conditions, including cancer.

Key Findings of The Study

• By grade, grade 1 segment dominated the market in 2022.
• By treatment, erythropoietin-stimulating agents segment dominated the market in 2022.
• On the basis of end user, the hospital segment dominated the market in 2022.
• By region, North America dominated the market in 2022. However, Asia-Pacific is expected to be the fastest growing region during the forecast period with CAGR of 7.5%